Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Saved in:
| Title: | Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems. |
|---|---|
| Authors: | Ross TT; Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Crowley C; Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Kelly KL; Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Rinaldi A; Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Beebe DA; Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Lech MP; Inflammation and Immunology Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Martinez RV; Inflammation and Immunology Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Carvajal-Gonzalez S; Early Clinical Development, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Boucher M; Drug Safety Research and Development, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Hirenallur-Shanthappa D; Comparative Medicine, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Morin J; Comparative Medicine, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Opsahl AC; Drug Safety Research and Development, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Vargas SR; Drug Safety Research and Development, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Bence KK; Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Pfefferkorn JA; Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts., Esler WP; Internal Medicine Research Unit, Pfizer Worldwide Research and Development, Cambridge Massachusetts. Electronic address: William.Esler@Pfizer.com. |
| Source: | Cellular and molecular gastroenterology and hepatology [Cell Mol Gastroenterol Hepatol] 2020; Vol. 10 (4), pp. 829-851. Date of Electronic Publication: 2020 Jun 09. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Gastroenterological Association Country of Publication: United States NLM ID: 101648302 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-345X (Electronic) Linking ISSN: 2352345X NLM ISO Abbreviation: Cell Mol Gastroenterol Hepatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
